Scleroderma

Last updated

Scleroderma
MercMorphea.JPG
A type of localized scleroderma known as morphea
Specialty Rheumatology
Usual onsetMiddle age [1]
TypesLocalized, systemic scleroderma [2]
CausesUnknown [2]
Risk factors Family history, certain genetic factors, exposure to silica [3] [4] [5]
Diagnostic method Based on symptoms, skin biopsy, blood tests [6]
Differential diagnosis Mixed connective tissue disease, systemic lupus erythematosus, polymyositis, dermatomyositis [1]
Treatment Supportive care [1]
Medication Corticosteroids, methotrexate, non-steroidal anti-inflammatory drugs (NSAIDs) [2]
Prognosis Localized: Normal life expectancy [7]
Systemic: Decreased life expectancy [3]
Frequency3 per 100,000 per year (systemic) [3]

Scleroderma is a group of autoimmune diseases that may result in changes to the skin, blood vessels, muscles, and internal organs. [2] [6] [8] The disease can be either localized to the skin or involve other organs, as well. [2] Symptoms may include areas of thickened skin, stiffness, feeling tired, and poor blood flow to the fingers or toes with cold exposure. [1] One form of the condition, known as CREST syndrome, classically results in calcium deposits, Raynaud's syndrome, esophageal problems, thickening of the skin of the fingers and toes, and areas of small, dilated blood vessels. [1]

Contents

The cause is unknown, but it may be due to an abnormal immune response. [2] Risk factors include family history, certain genetic factors, and exposure to silica. [3] [4] [5] The underlying mechanism involves the abnormal growth of connective tissue, which is believed to be the result of the immune system attacking healthy tissues. [6] Diagnosis is based on symptoms, supported by a skin biopsy or blood tests. [6]

While no cure is known, treatment may improve symptoms. [2] Medications used include corticosteroids, methotrexate, and non-steroidal anti-inflammatory drugs (NSAIDs). [2] Outcome depends on the extent of disease. [3] Those with localized disease generally have a normal life expectancy. [7] In those with systemic disease, life expectancy can be affected, and this varies based on subtype. [3] Death is often due to lung, gastrointestinal, or heart complications. [3]

About three per 100,000 people per year develop the systemic form. [3] The condition most often begins in middle age. [1] Women are more often affected than men. [1] Scleroderma symptoms were first described in 1753 by Carlo Curzio [9] and then well documented in 1842. [10] The term is from the Greek skleros meaning "hard" and derma meaning "skin". [11] [12]

Signs and symptoms

Arm of a person with scleroderma showing skin lesions Left Arm Scleroderma Patient.jpg
Arm of a person with scleroderma showing skin lesions
Dark, shiny skin on distal phalanges of both hands in systemic sclerosis Systemic sclerosis, changes on hands are allways bilateral.jpg
Dark, shiny skin on distal phalanges of both hands in systemic sclerosis

Potential signs and symptoms include: [13] [14] [15]

Cause

Scleroderma is caused by genetic and environmental factors. [4] [5] [16] [17] Mutations in HLA genes seem to play a crucial role in the pathogenesis of some cases; likewise silica, aromatic and chlorinated solvents, ketones, trichloroethylene, welding fumes, and white spirits exposure seems to contribute to the condition in a small proportion of affected persons. [4] [5] [16] [17] [18]

Pathophysiology

Scleroderma is characterised by increased synthesis of collagen (leading to the sclerosis), damage to small blood vessels, activation of T lymphocytes, and production of altered connective tissue. [19] Its proposed pathogenesis is the following: [20] [21] [22] [23] [24]

Vitamin D is implicated in the pathophysiology of the disease. An inverse correlation between plasma levels of vitamin D and scleroderma severity has been noted, and vitamin D is known to play a crucial role in regulating (usually suppressing) the actions of the immune system. [26]

Diagnosis

Typical scleroderma is classically defined as symmetrical skin thickening, with about 70% of cases also presenting with Raynaud's phenomenon, nail-fold capillary changes, and antinuclear antibodies. Affected individuals may experience systemic organ involvement. No single test for scleroderma works all of the time, hence diagnosis is often a matter of exclusion. Atypical scleroderma may show any variation of these changes without skin changes or with finger swelling only. [27]

Laboratory testing can show antitopoisomerase antibodies, like anti-scl70 (causing a diffuse systemic form), or anticentromere antibodies (causing a limited systemic form and the CREST syndrome). Other autoantibodies can be seen, such as anti-U3 or anti-RNA polymerase. [28] Antidouble-stranded DNA autoantibodies are likely to be present in serum.[ citation needed ]

Differential

Diseases that are often in the differential include: [29]

Classification

Scleroderma is characterised by the appearance of circumscribed or diffuse, hard, smooth, ivory-colored areas that are immobile and which give the appearance of hidebound skin, a disease occurring in both localised and systemic forms: [30]

Treatment

No cure for scleroderma is known, although relief of symptoms is often achieved; these include treatment of: [13] [31]

Systemic disease-modifying treatment with immunosuppressants is often used. [16] [32] [33] [34] [35] [36] Immunosuppressants used in its treatment include azathioprine, methotrexate, cyclophosphamide, mycophenolate, intravenous immunoglobulin, rituximab, sirolimus, alefacept, and the tyrosine kinase inhibitors, imatinib, nilotinib, and dasatinib. [16] [31] [32] [33] [34] [35] [36] [37]

Experimental therapies under investigation include endothelin receptor antagonists, tyrosine kinase inhibitors, beta-glycan peptides, halofuginone, basiliximab, alemtuzumab, abatacept, and haematopoietic stem cell transplantation. [38] [39]

Immunomodulatory agents in the treatment of scleroderma
INN Mechanism of action [40] [41] Route of administration [40] Pregnancy category [40] [42] Major toxicities [40]
Alefacept Monoclonal antibody to inhibit T lymphocyte activation by binding to CD2 portion of human leukocyte function antigen-3.IMB (US)Malignancies, injection site reactions, blood clots, lymphopenia, hepatotoxicity and infections.
Azathioprine Purine analogue that inhibits lymphocyte proliferation via conversion to mercaptopurine PO, IVD (Au) Myelosuppression and rarely malignancy, hepatitis, infection, hepatic sinusoidal obstruction syndrome and hypersensitivity reactions.
Cyclophosphamide Nitrogen mustard that cross-links DNA base pairs, leading to breakages and triggering apoptosis in haematopoietic cells.PO, IVD (Au)Vomiting, myelosuppression, haemorrhagic cystitis and rarely heart failure, pulmonary fibrosis, hepatic sinusoidal obstruction syndrome, malignancy and SIADH
Dasatinib Tyrosine kinase inhibitor against various proangiogenic growth factors (including PDGF and VEGF).POD (Au)Fluid retention, myelosuppression, haemorrhage, infections, pulmonary hypertension, electrolyte anomalies and uncommonly hepatotoxicity, heart dysfunction/failure, myocardial infarction, QT interval prolongation, renal failure and hypersensitivity.
Imatinib As abovePOD (Au)As above and rarely: GI perforation, avascular necrosis and rhabdomyolysis
Immunoglobulin Immunoglobulin, modulates the immune system.IVN/AVaries
Methotrexate Antifolate; inhibits dihydrofolate reductase.PO, IV, IM, SC, ITD (Au)Myeosuppression, pulmonary toxicity, hepatotoxicity, neurotoxicity and rarely kidney failure, hypersensitivity reactions, skin and bone necrosis, and osteoporosis
Mycophenolate Inosine monophosphate dehydrogenase inhibitor, leading to reduced purine biosynthesis in lymphocytes.PO, IVD (Au)Myelosuppression, blood clots, less commonly GI perforation/haemorrhage and rarely pancreatitis, hepatitis, aplastic anaemia and pure red cell aplasia.
Nilotinib As per dasatinibPOD (Au)As per imatinib
Rituximab Monoclonal antibody against CD20, which is expressed on B lymphocytesIVC (Au)Infusion-related reactions, infection, neutropenia, reduced immunoglobulin levels, arrhythmias, less commonly anaemia, thrombocytopenia, angina, myocardial infarction, heart failure, and rarely haemolytic anaemia, aplastic anaemia, serum sickness, severe skin conditions, pulmonary infiltrates, pneumonitis, cranial neuropathy (vision or hearing loss) and progressive multifocal leucoencephalopathy.
Sirolimus mTOR inhibitor, thereby reducing cytokine-induced lymphocyte proliferation.POC (Au) Neutropenia, hypokalaemia, interstitial lung disease, pericardial effusion, pleural effusion, less commonly pulmonary haemorrhage, nephrotic syndrome, and rarely hepatotoxicity and lymphoedema.
PO = Oral. IV = Intravenous. IM = Intramuscular. SC = Subcutaneous. IT = Intrathecal.

The preferred pregnancy category, above, is Australian, if available. If unavailable, an American one is substituted.

Prognosis

As of 2012, the five-year survival rate for systemic scleroderma was about 85%, whereas the 10-year survival rate was just under 70%. [43] This varies according to the subtype; while localized scleroderma rarely results in death, the systemic form can, and the diffuse systemic form carries a worse prognosis than the limited form. The major scleroderma-related causes of death are: pulmonary hypertension, pulmonary fibrosis, and scleroderma renal crisis. [28] People with scleroderma are also at a heightened risk for developing osteoporosis and for contracting cancer (especially liver, lung, haematologic, and bladder cancers). [44] Scleroderma is also associated with an increased risk of cardiovascular disease. [45]

According to a study of an Australian cohort, between 1985 and 2015, the average life expectancy of a person with scleroderma increased from 66 years to 74 years (the average Australian life expectancy increased from 76 to 82 years in the same period). [46]

Epidemiology

Scleroderma most commonly first presents between the ages of 20 and 50 years, although any age group can be affected. [13] [28] Women are four to nine times more likely to develop scleroderma than men. [28]

This disease is found worldwide. [28] In the United States, prevalence is estimated at 240 per million and the annual incidence of scleroderma is 19 per million people. [28] Likewise in the United States, it is slightly more common in African Americans than in their white counterparts. Choctaw Native Americans are more likely than Americans of European descent to develop the type of scleroderma that affects internal organs. [28] In Germany, the prevalence is between 10 and 150 per million people, and the annual incidence is between three and 28 per million people. [43] In South Australia, the annual incidence is 23 per million people, and the prevalence 233 per million people. [47]

Pregnancy

Scleroderma in pregnancy is a complex situation; it increases the risk to both mother and child. [48] Overall, scleroderma is associated with reduced fetal weight for gestational age. [48] The treatment for scleroderma often includes known teratogens such as cyclophosphamide, methotrexate, mycophenolate, etc., so careful avoidance of such drugs during pregnancy is advised. [48] In these cases hydroxychloroquine and low-dose corticosteroids might be used for disease control. [48]

See also

Related Research Articles

<span class="mw-page-title-main">Systemic scleroderma</span> Accumulation of collagen in the skin and internal organs

Systemic scleroderma, or systemic sclerosis, is an autoimmune rheumatic disease characterised by excessive production and accumulation of collagen, called fibrosis, in the skin and internal organs and by injuries to small arteries. There are two major subgroups of systemic sclerosis based on the extent of skin involvement: limited and diffuse. The limited form affects areas below, but not above, the elbows and knees with or without involvement of the face. The diffuse form also affects the skin above the elbows and knees and can also spread to the torso. Visceral organs, including the kidneys, heart, lungs, and gastrointestinal tract can also be affected by the fibrotic process. Prognosis is determined by the form of the disease and the extent of visceral involvement. Patients with limited systemic sclerosis have a better prognosis than those with the diffuse form. Death is most often caused by lung, heart, and kidney involvement. The risk of cancer is increased slightly.

<span class="mw-page-title-main">Sjögren syndrome</span> Autoimmune disease affecting the bodys moisture-producing glands

Sjögren syndrome or Sjögren's syndrome is a long-term autoimmune disease that primarily affects the body's exocrine glands, particularly the lacrimal and salivary glands. Common symptoms include dry mouth, dry eyes and often seriously affects other organ systems, such as the lungs, kidneys, and nervous system.

<span class="mw-page-title-main">Autoimmunity</span> Immune response against an organisms own healthy cells

In immunology, autoimmunity is the system of immune responses of an organism against its own healthy cells, tissues and other normal body constituents. Any disease resulting from this type of immune response is termed an "autoimmune disease". Prominent examples include celiac disease, diabetes mellitus type 1, Henoch–Schönlein purpura, systemic lupus erythematosus, Sjögren syndrome, eosinophilic granulomatosis with polyangiitis, Hashimoto's thyroiditis, Graves' disease, idiopathic thrombocytopenic purpura, Addison's disease, rheumatoid arthritis, ankylosing spondylitis, polymyositis, dermatomyositis, and multiple sclerosis. Autoimmune diseases are very often treated with steroids.

<span class="mw-page-title-main">Antinuclear antibody</span> Autoantibody that binds to contents of the cell nucleus

Antinuclear antibodies are autoantibodies that bind to contents of the cell nucleus. In normal individuals, the immune system produces antibodies to foreign proteins (antigens) but not to human proteins (autoantigens). In some cases, antibodies to human antigens are produced; these are known as autoantibodies.

<span class="mw-page-title-main">Raynaud syndrome</span> Medical condition in which spasm of arteries causes episodes of reduced blood flow

Raynaud syndrome, also known as Raynaud's phenomenon, is a medical condition in which the spasm of small arteries causes episodes of reduced blood flow to end arterioles. Typically the fingers, and, less commonly, the toes, are involved. Rarely, the nose, ears, nipples, or lips are affected. The episodes classically result in the affected part turning white and then blue. Often, numbness or pain occurs. As blood flow returns, the area turns red and burns. The episodes typically last minutes but can last several hours. The condition is named after the physician Auguste Gabriel Maurice Raynaud, who first described it in his doctoral thesis in 1862.

<span class="mw-page-title-main">CREST syndrome</span> Connective tissue disorder

CREST syndrome, also known as the limited cutaneous form of systemic sclerosis (lcSSc), is a multisystem connective tissue disorder. The acronym "CREST" refers to the five main features: calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.

Connective tissue disease, also known as connective tissue disorder, or collagen vascular diseases, refers to any disorder that affect the connective tissue. The body's structures are held together by connective tissues, consisting of two distinct proteins: elastin and collagen. Tendons, ligaments, skin, cartilage, bone, and blood vessels are all made of collagen. Skin and ligaments contain elastin. The proteins and the body's surrounding tissues may suffer damage when these connective tissues become inflamed.

<span class="mw-page-title-main">Morphea</span> Form of scleroderma involving isolated patches of hardened skin

Morphea is a form of scleroderma that mainly involves isolated patches of hardened skin on the face, hands, and feet, or anywhere else on the body, usually with no internal organ involvement. However, in Deep Morphea inflammation and sclerosis can be found in the deep dermis, panniculus, fascia, superficial muscle and bone.

Mixed connective tissue disease (MCTD) is a systemic autoimmune disease that shares characteristics with at least two other systemic autoimmune diseases, including systemic sclerosis (Ssc), systemic lupus erythematosus (SLE), polymyositis/dermatomyositis (PM/DM), and rheumatoid arthritis. The idea behind the "mixed" disease is that this specific autoantibody is also present in other autoimmune diseases such as systemic lupus erythematosus, polymyositis, scleroderma, etc. MCTD was characterized as an individual disease in 1972 by Sharp et al., and the term was introduced by Leroy in 1980.

Type V collagen is a form of fibrillar collagen associated with classical Ehlers-Danlos syndrome. It is found within the dermal/epidermal junction, placental tissues, as well as in association with tissues containing type I collagen.

Scleromyositis, is an autoimmune disease. People with scleromyositis have symptoms of both systemic scleroderma and either polymyositis or dermatomyositis, and is therefore considered an overlap syndrome. Although it is a rare disease, it is one of the more common overlap syndromes seen in scleroderma patients, together with MCTD and Antisynthetase syndrome. Autoantibodies often found in these patients are the anti-PM/Scl (anti-exosome) antibodies.

An overlap syndrome is a medical condition which shares features of at least two more widely recognised disorders. Examples of overlap syndromes can be found in many medical specialties such as overlapping connective tissue disorders in rheumatology, and overlapping genetic disorders in cardiology.

<span class="mw-page-title-main">Autoimmune disease</span> Disorders of adaptive immune system

An autoimmune disease is a condition that results from an anomalous response of the adaptive immune system, wherein it mistakenly targets and attacks healthy, functioning parts of the body as if they were foreign organisms. It is estimated that there are more than 80 recognized autoimmune diseases, with recent scientific evidence suggesting the existence of potentially more than 100 distinct conditions. Nearly any body part can be involved.

<span class="mw-page-title-main">Systemic vasculitis</span> Medical condition

Necrotizing vasculitis, also called systemic necrotizing vasculitis, is a general term for the inflammation of veins and arteries that develops into necrosis and narrows the vessels.

<span class="mw-page-title-main">Lupus</span> Autoimmune disease in which the immune system attacks healthy tissue

Lupus, technically known as systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary among people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms.

Undifferentiated connective tissue disease (UCTD) is a disease in which the connective tissues are targeted by the immune system. It is a serological and clinical manifestation of an autoimmune disease. When there is proof of an autoimmune disease, it will be diagnosed as UCTD if the disease does not correspond to any criterion of specific autoimmune disease. This is also the case of major rheumatic diseases whose early phase was defined by LeRoy et al. in 1980 as undifferentiated connective tissue disease.

<span class="mw-page-title-main">Anti-SSA/Ro autoantibodies</span> Type of anti-nuclear autoantibodies

Anti-SSA autoantibodies are a type of anti-nuclear autoantibodies that are associated with many autoimmune diseases, such as systemic lupus erythematosus (SLE), SS/SLE overlap syndrome, subacute cutaneous lupus erythematosus (SCLE), neonatal lupus and primary biliary cirrhosis. They are often present in Sjögren's syndrome (SS). Additionally, Anti-Ro/SSA can be found in other autoimmune diseases such as systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), rheumatoid arthritis (RA), and mixed connective tissue disease (MCTD), and are also associated with heart arrhythmia.

<span class="mw-page-title-main">Antisynthetase syndrome</span> Medical condition

Antisynthetase syndrome (ASS) is a multisystematic autoimmune disease associated with inflammatory myositis, interstitial lung disease, and antibodies directed against various synthetases of aminoacyl-transfer RNA. Other common symptoms include mechanic's hands, Raynaud's phenomenon, arthritis, and fever.

Autoimmunity refers to a pathological immune response of the body's immune system against itself. Autoimmune disease is widely recognized to be significantly more common in women than in men, and often presents differently between the sexes. The reasons for these disparities are still under investigation, but may in part involve the presence of an additional X chromosome in women, as well as the higher presence of female sex hormones such as estrogen. The risk, incidence, and character of autoimmune disease in women may also be associated with female-specific physiological changes, such as hormonal shifts during menses, pregnancy, and menopause.

References

  1. 1 2 3 4 5 6 7 "Scleroderma". NORD (National Organization for Rare Disorders). 2007. Archived from the original on 8 September 2016. Retrieved 14 July 2017.
  2. 1 2 3 4 5 6 7 8 "Scleroderma". GARD. 2017. Archived from the original on 25 January 2017. Retrieved 14 July 2017.
  3. 1 2 3 4 5 6 7 8 Jameson L (2018). "Chapter 353". Harrison's Principles of Internal Medicine (20th ed.). McGraw Hill.
  4. 1 2 3 4 Barnes J, Mayes MD (March 2012). "Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers". Current Opinion in Rheumatology. 24 (2): 165–70. doi:10.1097/BOR.0b013e32834ff2e8. PMID   22269658. S2CID   24050211.
  5. 1 2 3 4 Greenblatt MB, Aliprantis AO (January 2013). "The immune pathogenesis of scleroderma: context is everything". Current Rheumatology Reports. 15 (1): 297. doi:10.1007/s11926-012-0297-8. PMC   3539168 . PMID   23288576.
  6. 1 2 3 4 "Handout on Health: Scleroderma". NIAMS. August 2016. Archived from the original on 4 July 2017. Retrieved 15 July 2017.
  7. 1 2 Unsal E (2006). Current Opinions in Pediatric Rheumatology. Nova Publishers. p. 302. ISBN   9781594548710. Archived from the original on 2017-09-06.
  8. ↑ Denton CP, Khanna D (October 2017). "Systemic sclerosis". Lancet. 390 (10103): 1685–1699. doi:10.1016/s0140-6736(17)30933-9. PMID   28413064. S2CID   22247432.
  9. ↑ Mackay IR, Rose NR (2006). The Autoimmune Diseases. Academic Press. p. 369. ISBN   9780080454740.
  10. ↑ Firestein GS, Kelley WN, Budd RC (2012). Kelley's Textbook of Rheumatology. Elsevier Health Sciences. p. 1366. ISBN   978-1437717389. Archived from the original on 2017-08-04.
  11. ↑ Harper D. "scleroderma". Online Etymology Dictionary .
  12. ↑ σκληρός, δέρμα . Liddell, Henry George ; Scott, Robert ; A Greek–English Lexicon at the Perseus Project.
  13. 1 2 3 Hajj-ali, RA (June 2013). "Systemic Sclerosis". Merck Manual Professional. Merck Sharp & Dohme Corp. Archived from the original on 6 March 2014. Retrieved 5 March 2014.
  14. ↑ Jimenez, SA, Cronin, PM, Koenig, AS, O'Brien, MS, Castro, SV (15 February 2012). Varga, J, Talavera, F, Goldberg, E, Mechaber, AJ, Diamond, HS (eds.). "Scleroderma Clinical Presentation". Medscape Reference. WebMD. Archived from the original on 6 March 2014. Retrieved 5 March 2014.
  15. ↑ Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J (2011). Harrison's Principles of Internal Medicine (18th ed.). New York: McGraw-Hill Professional. ISBN   978-0-07174889-6.[ page needed ]
  16. 1 2 3 4 Balbir-Gurman A, Braun-Moscovici Y (February 2012). "Scleroderma – new aspects in pathogenesis and treatment". Best Practice & Research. Clinical Rheumatology. 26 (1): 13–24. doi:10.1016/j.berh.2012.01.011. PMID   22424190.
  17. 1 2 Dospinescu P, Jones GT, Basu N (March 2013). "Environmental risk factors in systemic sclerosis". Current Opinion in Rheumatology. 25 (2): 179–83. doi:10.1097/BOR.0b013e32835cfc2d. PMID   23287382. S2CID   37543720.
  18. ↑ Marie I, Gehanno JF, Bubenheim M, Duval-Modeste AB, Joly P, Dominique S, et al. (February 2014). "Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature". Autoimmunity Reviews. 13 (2): 151–56. doi:10.1016/j.autrev.2013.10.002. PMID   24129037.
  19. ↑ Valančienė G, Jasaitienė D, Valiukevičienė S (2010). "Pathogenesis and treatment modalities of localized scleroderma" (PDF). Medicina. 46 (10): 649–56. doi: 10.3390/medicina46100092 . PMID   21393982. Archived (PDF) from the original on 2014-03-06.
  20. ↑ Katsumoto TR, Whitfield ML, Connolly MK (2011). "The pathogenesis of systemic sclerosis". Annual Review of Pathology. 6: 509–37. doi:10.1146/annurev-pathol-011110-130312. PMID   21090968.
  21. ↑ Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R (August 2011). "Angiogenic cytokines and growth factors in systemic sclerosis". Autoimmunity Reviews. 10 (10): 590–94. doi:10.1016/j.autrev.2011.04.019. PMID   21549861.
  22. ↑ Cipriani P, Marrelli A, Liakouli V, Di Benedetto P, Giacomelli R (August 2011). "Cellular players in angiogenesis during the course of systemic sclerosis". Autoimmunity Reviews. 10 (10): 641–46. doi:10.1016/j.autrev.2011.04.016. PMID   21549220.
  23. ↑ Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, et al. (August 2011). "B cells in systemic sclerosis: a possible target for therapy". Autoimmunity Reviews. 10 (10): 624–30. doi:10.1016/j.autrev.2011.04.013. PMID   21545850.
  24. ↑ Hunzelmann N, Krieg T (May 2010). "Scleroderma: from pathophysiology to novel therapeutic approaches". Experimental Dermatology. 19 (5): 393–400. doi:10.1111/j.1600-0625.2010.01082.x. PMID   20507361. S2CID   40400573.
  25. ↑ Leask A (June 2011). "The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis". Pharmacological Research. 63 (6): 502–03. doi:10.1016/j.phrs.2011.01.011. PMID   21315153.
  26. ↑ Arnson Y, Amital H, Agmon-Levin N, Alon D, Sánchez-Castañón M, López-Hoyos M, et al. (June 2011). "Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature". Autoimmunity Reviews. 10 (8): 490–94. doi:10.1016/j.autrev.2011.02.002. PMID   21320645.
  27. ↑ Jimenez, SA, Cronin, PM, Koenig, AS, O'Brien, MS, Castro, SV (15 February 2012). Varga, J, Talavera, F, Goldberg, E, Mechaber, AJ, Diamond, HS (eds.). "Scleroderma Workup". Medscape Reference. WebMD. Archived from the original on 6 March 2014. Retrieved 6 March 2014.
  28. 1 2 3 4 5 6 7 Jimenez, SA, Cronin, PM, Koenig, AS, O'Brien, MS, Castro, SV (15 February 2012). Varga, J, Talavera, F, Goldberg, E, Mechaber, AJ, Diamond, HS (eds.). "Scleroderma". Medscape Reference. WebMD. Archived from the original on 6 March 2014. Retrieved 5 March 2014.
  29. ↑ Jimenez, SA, Cronin, PM, Koenig, AS, O'Brien, MS, Castro, SV (15 February 2012). Varga, J, Talavera, F, Goldberg, E, Mechaber, AJ, Diamond, HS (eds.). "Scleroderma Differential Diagnoses". Medscape Reference. WebMD. Archived from the original on 6 March 2014. Retrieved 6 March 2014.
  30. ↑ Elston W, James WD, Berger TG, Dirk M (2006). Andrew's diseases of the skin: clinical dermatology (10 ed.). Philadelphia, PA: Saunders Elsevier. pp.  169–172. ISBN   978-0808923510.
  31. 1 2 Walker KM, Pope J (August 2012). "Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts". Seminars in Arthritis and Rheumatism. 42 (1): 42–55. doi:10.1016/j.semarthrit.2012.01.003. PMID   22464314.
  32. 1 2 Fett N (July–August 2013). "Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies". Clinics in Dermatology. 31 (4): 432–37. doi:10.1016/j.clindermatol.2013.01.010. PMID   23806160.
  33. 1 2 Shah AA, Wigley FM (April 2013). "My approach to the treatment of scleroderma". Mayo Clinic Proceedings. 88 (4): 377–93. doi:10.1016/j.mayocp.2013.01.018. PMC   3666163 . PMID   23541012.
  34. 1 2 Kowal-Bielecka O, Bielecki M, Kowal K (2013). "Recent advances in the diagnosis and treatment of systemic sclerosis" (PDF). Polskie Archiwum Medycyny Wewnetrznej. 123 (1–2): 51–58. PMID   23344666. Archived (PDF) from the original on 2014-03-06.
  35. 1 2 Beyer C, Dees C, Distler JH (January 2013). "Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis". Archives of Dermatological Research. 305 (1): 1–8. doi:10.1007/s00403-012-1304-7. PMID   23208311. S2CID   25073736.
  36. 1 2 Leask A (June 2012). "Emerging targets for the treatment of scleroderma". Expert Opinion on Emerging Drugs. 17 (2): 173–79. doi:10.1517/14728214.2012.678833. PMID   22533795. S2CID   29026417.
  37. ↑ Manno R, Boin F (November 2010). "Immunotherapy of systemic sclerosis". Immunotherapy. 2 (6): 863–78. doi:10.2217/imt.10.69. PMC   3059511 . PMID   21091117.
  38. ↑ Postlethwaite AE, Harris LJ, Raza SH, Kodura S, Akhigbe T (April 2010). "Pharmacotherapy of systemic sclerosis". Expert Opinion on Pharmacotherapy. 11 (5): 789–806. doi:10.1517/14656561003592177. PMC   2837533 . PMID   20210685.
  39. ↑ Ong VH, Denton CP (May 2010). "Innovative therapies for systemic sclerosis". Current Opinion in Rheumatology. 22 (3): 264–72. doi:10.1097/BOR.0b013e328337c3d6. PMID   20190640. S2CID   24631979.
  40. 1 2 3 4 Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN   978-0-9805790-9-3.[ page needed ]
  41. ↑ Brunton, L, Chabner, B, Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN   978-0-07-162442-8.[ page needed ]
  42. ↑ "Medscape Multispecialty – Home page". WebMD. Archived from the original on 13 November 2013. Retrieved 27 November 2013.[ full citation needed ]
  43. 1 2 Sticherling M (October 2012). "Systemic sclerosis-dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings". Journal der Deutschen Dermatologischen Gesellschaft. 10 (10): 705–18, quiz 716. doi: 10.1111/j.1610-0387.2012.07999.x . PMID   22913330. S2CID   7422759.
  44. ↑ Calderon LM, Domsic RT, Shah AA, Pope JE (May 2023). "Preventative Care in Scleroderma: What Is the Best Approach to Bone Health and Cancer Screening?". Rheumatic Disease Clinics of North America. 49 (2): 411–423. doi:10.1016/j.rdc.2023.01.011. PMC   10845237 . PMID   37028844.
  45. ↑ Cen X, Feng S, Wei S, Yan L, Sun L (November 2020). "Systemic sclerosis and risk of cardiovascular disease: A PRISMA-compliant systemic review and meta-analysis of cohort studies". Medicine. 99 (47): e23009. doi:10.1097/MD.0000000000023009. PMC   7676589 . PMID   33217802.
  46. ↑ Kennedy N, Walker J, Hakendorf P, Roberts-Thomson P (23 March 2018). "Improving life expectancy of patients with scleroderma: results from the South Australian Scleroderma Register". Internal Medicine Journal. 48 (8): 951–56. doi:10.1111/imj.13799. PMID   29573101. S2CID   4230441.
  47. ↑ Nikpour M, Stevens WM, Herrick AL, Proudman SM (December 2010). "Epidemiology of systemic sclerosis". Best Practice & Research. Clinical Rheumatology. 24 (6): 857–69. doi:10.1016/j.berh.2010.10.007. PMID   21665131.
  48. 1 2 3 4 Lidar M, Langevitz P (May 2012). "Pregnancy issues in scleroderma". Autoimmunity Reviews. 11 (6–7): A515–19. doi:10.1016/j.autrev.2011.11.021. PMID   22155199.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.